Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 14/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337115 | 0.90 | S1PR3 (0.61) | S1PR3CYP19A1P2RX4 | |
| SCHEMBL336878 | 0.86 | S1PR3 (0.64) | S1PR3LMNATSHRSMN1; SMN2 | |
| SCHEMBL337334 | 0.84 | S1PR3 (0.56) | S1PR3CYP19A1P2RX4 | |
| SCHEMBL337335 | 0.81 | S1PR3 (0.53) | S1PR3LMNASMN1; SMN2 | |
| SCHEMBL336721 | 0.81 | S1PR3 (0.53) | S1PR3LMNASMN1; SMN2 | |
| SCHEMBL336720 | 0.81 | S1PR3 (0.53) | S1PR3LMNASMN1; SMN2 | |
| SCHEMBL8506509 | 0.81 | SMN1; SMN2 (0.58) | LMNATSHRSMN1; SMN2CYP19A1P2RX4 | |
| SCHEMBL28768520 | 0.81 | LMNA (0.71) | LMNATSHRSMN1; SMN2CYP19A1P2RX4 | |
| SCHEMBL28712753 | 0.79 | ALDH1A1 (0.59) | LMNATSHRSMN1; SMN2CYP19A1P2RX4 | |
| SCHEMBL8233577 | 0.77 | S1PR3 (0.49) | S1PR3CYP19A1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | S1PR1, S1PR2, S1PR3 | S1PR3 3/4885LMNA 3435/4885TSHR 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.